EU regulation of medical devices and pharmaceuticals in comparative perspective

Review of Policy Research

Volumn 24, Issue 5, 2007, Pages 385-405

  Altenstetter, Christa ^a   Permanand, Govin ^b  

^a CITY UNIVERSITY OF NEW YORK   (United States)

^b LONDON SCHOOL OF ECONOMICS   (United Kingdom)

Author keywords

EU regulatory regimes; Free movement rules; Health protection schemes; Medical devices; Pharmaceuticals; Product life cycle

Indexed keywords

EUROPEAN UNION; HEALTH CARE; HEALTH POLICY; INSTITUTIONAL FRAMEWORK; POLICY MAKING; PUBLIC HEALTH; REGULATORY FRAMEWORK;

EURASIA; EUROPE;

EID: 35349003626     PISSN: 1541132X     EISSN: 15411338     Source Type: Journal    
DOI: 10.1111/j.1541-1338.2007.00291.x     Document Type: Article

References (52)

1. Abraham, J., & Lewis, G. (2000). Regulating medicines in Europe: Competition, expertise & public health. London: Routledge.
2. Altenstetter, C. (2007). Medical devices. European Union policymaking and the implementation of health and patient safety in France. New Brunswick, NJ: Transaction Publishers.
3. Andersen, S., & Eliassen, K.-A. (1995). EU lobbying: The new research agenda. European Journal of Political Research, 27, 427-441.
4. Armstrong, K. (2002). Mutual recognition. In C. Barnard & J. Scott (Eds.). The law of the single European market. Unpacking the premises (pp. 225-267). Oxford, UK and Portland, OR: Hart Publishing.
5. Baldwin, R., & Cave, M. (1999). Understanding regulation: Theory, strategy and practice. Oxford, UK: Oxford University Press.
6. Baldwin, R., Scott, C., & Hood, C. (Eds.) (1998). A reader on regulation. Oxford, UK: Oxford University Press.
7. Bock, A.-K., Rodriguez-Cerezo, E., Hüsing, B., Bührlen, B., & Nusser, M. (2005). Human tissue-engineered products: Potential socio-economic impacts of a new European regulatory framework for authorization, supervision and vigilance (European Science and Technology Observatory Report EUR 21838). Retrieved August 23, 2007, from ftp://ftp.jrc.es/pub/EURdoc/eur21838en.pdf
8. Bomberg, E., & Stubb, A. C.-G. (2003). The European Union: How does it work? Oxford, UK: Oxford University Press.
9. Braithwaite, J., & Drahos, P. (2000). Global business regulation. Cambridge, UK: Cambridge University Press.
10. Burns, L. R. (2005). The business of healthcare innovation. Cambridge, UK: Cambridge University Press.
11. Cecchini, P., Catinat, M., & Jacquemin, A. (1988). The European challenge 1992: The benefits of a single market. Aldershot, UK: Wildwood House.
12. Chambers, G., & Belcher, P. (1994). The consumption of medicines in the European Union. In E. Mossialos, C. Ranos, & B. Abel-Smith (Eds.), Cost containment, pricing and financing of pharmaceuticals in the European Community: The policy-makers' view. Athens: LSE Health and Pharmetrica S.A.
13. Cheng, M. (2003, April). Medical device regulation and policy development. Draft Theme Paper. The World Bank. International Forum for Promoting Safe and Affordable Medical Technology in Developing Countries, Washington, D.C.
14. Cutler, I. (1998). The role of standards. In J. Adcock, S. Sorrel, & J. Watts (Eds.), Medical devices manual (Revised ed., pp 1-20). Haslemere, UK: Euromed Communications Ltd.
15. Cutler, I. (1999, March). Progress on global harmonization and mutual recognition agreements. IBC UK Conference Limited. Director of European Regulatory Affairs, Smith & Nephew PLC, London.
16. Daemmrich, A. (2004). Pharmacopolitics: Drug regulation in the United States and Germany. Chapel Hill: University of North Carolina Press.
17. Davis, P. (1997). Managing medicines - public policy and therapeutic drugs. State of Health Series. Buckingham, UK: Open University Press.
18. EUCOMED. (2000). European medical technologies and devices: Industry profile 2000. Brussels, Belgium: EUCOMED.
19. EUCOMED. (2003). European medical technologies and devices: Industry profile 2003. Brussels, Belgium: Eucomed.
20. Egan, M. (2002). Constructing a European market. Standards, regulation, and governance. Oxford, UK and New York: Oxford University Press.
21. European Commission. (2005, May). Enterprise and Industry Directorate General/Consumer Goods. Consultation paper. Human Tissue Engineering and Beyond: Proposal for a Community Regulatory Framework on Advanced Therapies.
22. Faunce, T. (2006). Toward a treaty on safety and cost effectiveness on pharmaceuticals and medical devices: Enhancing an endangered global public good. Globalization and Health, 2, 5.
23. Feick, J. (2002). Regulatory Europeanization, national autonomy and regulatory effectiveness: Marketing authorization for pharmaceuticals (Max-Planck-Institut für Gesellschaftsforschung Working Paper 02/ 6). Köln, Germany.
24. George, A., & Bennett, A. (2004). Case studies and theory development. Cambridge, MA: MIT Press.
25. Greenwood, J. (1995). The pharmaceutical industry. A European business alliance that works. In J. Greenwood (Ed.), European casebook on business alliances (pp. 69-98). London: Prentice Hall.
26. Hanson, D. (2005). CE marking, product standards and world trade. Cheltenham, UK: Edward Elgar.
27. Héritier, A., Knill, C., Mingers, S., & Rhodes, B. (1996). Ringing the changes in Europe. Regulatory competition and the transformation of the state. Berlin, Germany: De Gruyter.
28. Higson, G. (2002). Medical device safety. The regulation of medical devices for public health and safety. Published by Institute of Physics Publishing. IOP Publishing Ltd. 2002. Institute of Physics Publishing, Direct House, Temple Back, Bristol, UK.
29. Hodges, C. (2004a). Do we need a European medical devices agency? Medical Law Review, 12, 268-284.
30. Hodges, C. (2004b). The regulation of medicinal products and medical devices. In Andrew Grubb (Ed., assisted by Judith Laing), Principles of medical law (pp. 911-984). Oxford, UK: Oxford University Press.
31. Hodges, C. (2005). European regulation of consumer product safety. Oxford, UK: Oxford University Press.
32. Hollingsworth, J. R., Schmitter, P., & Streeck, W. (1994). Capitalism, sectors, institutions, and performance. In J. R. Hollingsworth, P. Schmitter, & W. Streeck (Eds.), Governing capitalist economies. Performance and control of economic sectors (pp. 3-16). New York: Oxford University Press.
33. House of Commons. (2005). The Influence of the pharmaceutical industry - fourth report of session 2004-2005 Vol. 1. Report together with formal minutes. London: The Stationary Office.
34. Jeffreys, B. (2001). The regulation of medical devices and the role of the Medical Devices Agency. British Journal of Clinical Pharmacology, 52, 229-235.
35. Joerges, C., & Vos, E. (1999). EU committees: Social regulation, law and politics. Oxford, UK and Portland, OR: Hart Publishing.
36. Jordana, J., & Levi-Faur, D. (2004). The politics of regulation. Institutions and regulatory reform for the age of governance. Cheltenham, UK: Edward Elgar.
37. Kent, J., & Faulkner, A. (2002). Regulating human implant technologies in Europe. Understanding the new era in medical device regulation. Health, Risk & Society, 4, 189-209.
38. MDEG. (2002). Report of the functioning of the Medical Devices Directive (93/42/EC of June 14, 1993). Medical Devices Experts Group Final Report 05-06-2002 Coll 1. European Commission: DG Enterprise, Bruxelles.
39. Majone, G. (1996). Regulating Europe. London: Routledge.
40. Majone, G. (2003). The politics of regulation and regulatory institutions. In J. Hayward & A. Menon (Eds.), Governing Europe (pp. 298-312). Oxford, UK: Oxford University Press.
41. MiEF. (2004). Medicines in Europe: Citizens' successes. Prescrire Internationale, 24, 542-548.
42. Mintzes, B., Barer, M., Kravitz, L., Kazanjian, A., Bassett, K., Lexchin, J., et al. (2002). Influence of direct to consumer pharmaceutical advertising and patients - requests on prescribing decisions: Two-site cross sectional survey. British Medical Journal, 324, 278-279.
43. Mossialos, E., & McKee, M. (2002). EU law and the social character of health care. Brussels, Germany: P.I.E. Lang Publishers.
44. Nambu, T., Rapp, R., & Rozek, R. (1998). Regulatory influences on the decision to introduce pharmaceutical products in Japan. The Journal of World Intellectual Property, 1, 763-799.
45. OECD. (1998). Regulation. Paris: Organization for Economic Cooperation and Development.
46. Pelkmans, J., Vos, E., & Di Mauro, L. (2000). Reforming product regulation in the EU. In G. Galli & J. Pelkmans (Eds.), Regulatory reform and competitiveness in Europe (pp. 238-291). Cheltenham and Northampton, MA: Edward Elgar Publishing Limited.
47. Permanand, G. (2006). EU pharmaceutical regulation: The politics of policy-making. Manchester, UK: Manchester University Press.
48. Permanand, G., & Mossialos, E. (2005). Constitutional asymmetry and pharmaceutical policy-making in the European Union. Journal of European Public Policy, 12, 687-709.
49. Rosenthal, M., Berndt, E., Donohue, J., Frank, R., & Epstein, A. (2002). Promotion of prescription drugs to consumers. New England Journal of Medicine, 346, 498-505.
50. Scharpf, F. (1999). Governing in Europe. Effective and democratic? Oxford, UK and New York: Oxford University Press.
51. Vos, E. (1999). Institutional frameworks of community health and safety regulation, committees, agencies and private bodies. Oxford: Hart Publishing.
52. Wallace, H., Wallace, W., & Pollack, M. A. (2005). Policy-making in the European Union (5th ed.). Oxford: Oxford University Press.